Bioxel Retains API Manufacturers to Scale-Up Cancer Ingredients

Bioxel Pharma, Inc. has entered into two separate letters of intent with companies specialized in pharmaceutical API manufacturing. Under the terms of the agreements, these companies will perform the commercial scale-up of specific steps of Bioxel’s manufacturing process for semi-synthetic taxanes.

“These agreements represent a key milestone in the industrial scale-up of our technologies and the commercialization of our new taxane products,” said Pascal Delmas, president and chief executive officer of Bioxel Pharma. “We have aligned ourselves with industry leaders that have the facilities and pharmaceutical expertise to accelerate our development and bring our next products on stream.”

In the coming weeks, Bioxel expects to execute contract development and manufacturing agreements with both of these new partners and continue building its taxane product line.

In 2005 Bioxel filed two patents covering the synthetic conversion of 9-DHB to paclitaxel and docetaxel. 9-DHB is a side stream taxane that the company produced during the isolation and purification of natural paclitaxel, a product the company presently markets. These technologies allow for synthetic production of both paclitaxel and docetaxel, two of the world’s most widely used cancer therapy ingredients.